Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML.

Ricardo Ballesteros-Ramírez Sandra QuijanoJulio SolanoCamila Ordoñez-ReyesMaría V HerreraRául Murillo Susana FiorentinoMónica Arevalo-Zambrano

Published in: Journal of cancer epidemiology (2020)

This retrospective study allowed us to know the epidemiology of AML in a reference Colombian Hospital. Additionally, in our knowledge, it is the first study that reports the RDI in consolidation with HIDAC in Latin America as a prognostic factor that directly impacts the OS.

Keyphrases

prognostic factors
acute myeloid leukemia
healthcare
adverse drug
allogeneic hematopoietic stem cell transplantation
risk factors
high intensity
acute lymphoblastic leukemia